Audentes Therapeutics, Inc. (NASDAQ:BOLD) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Contract.

On July 12, 2017, Audentes Therapeutics, Inc. (the “Company”) entered into a lease (the “Lease”) with Britannia Gateway II Limited Partnership, to which the Company will lease an additional space, resulting in a total of 26,553 leased square feet, at 201 Gateway Boulevard in South San Francisco, California 94063. The Lease commences on February 1, 2018 for an eight-year term, with an option to extend the term for one additional eight-year period. The Company’s annual base rent for the premises will be approximately $1.5 million for the first year of the Lease, and will increase by 3% each year thereafter. Under the Lease, the Company will have approximately $1.4 million for tenant improvements.

Item 1.01. Creation of a Direct Financial Obligation or an Obligation Under an Off-balance Sheet Arrangement of a Registrant.

The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 1.01.

Item 1.01 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 12, 2017, Jonathan Silverstein notified the Company of his decision to resign from the Company’s Board of Directors effective as of the same date. Additionally, on July 12, 2017, Thomas Woiwode notified the Company of his decision to resign from the Company’s Board of Directors effective as of the same date. Neither resignation was due to any disagreement with the Company.

About Audentes Therapeutics, Inc. (NASDAQ:BOLD)

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company’s subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.